Mycophenolate Mofetil Hexal

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Hexal, is an antimetabolite immunosuppressant presented as a tablet for oral use. It is used to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH USA supplies Mycophenolate Mofetil Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is employed in immunosuppressive regimens targeting organ transplantation and autoimmune kidney disease. - Kidney transplant rejection: reduces the risk of acute and chronic graft rejection. - Heart transplant rejection: helps maintain cardiac graft function by suppressing lymphocyte activity. - Lupus nephritis: controls renal inflammation and slows disease progression.

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may be watery. - Headache: occasional throbbing pain. - Tremor: fine shaking of hands or limbs. - Abdominal pain: cramping or discomfort. - Infections: increased susceptibility to common bacterial or viral infections.

Serious or Rare Side Effects: - Leukopenia: significant drop in white blood cells. - Anemia: reduced red blood cell count leading to fatigue. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy: increased risk of certain cancers with long‑term use. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

When prescribing Mycophenolate Mofetil, clinicians should observe several safety precautions. - Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Assess renal function: adjust therapy based on creatinine clearance and kidney status. - Evaluate liver enzymes: check hepatic function periodically. - Avoid live vaccines: live attenuated vaccines can cause infection under immunosuppression. - Use effective contraception: teratogenic risk requires reliable birth control for both sexes. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: combined use markedly increases bone marrow suppression. - Cyclosporine or tacrolimus: may raise mycophenolic acid levels, increasing toxicity risk. - Cholestyramine or other bile‑acid sequestrants: reduce absorption of mycophenolate.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: may modestly decrease drug bioavailability. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Non‑live vaccines: immunogenicity may be reduced; timing should be coordinated with the treating physician.